-
Protease Inhibitor Cocktail for α-Synuclein Workflows
2026-09-22
Protect α-synuclein, chromogranin A, and phosphoprotein measurements during cell or tissue disruption with an EDTA-free, broad-spectrum formulation. This workflow-focused guide shows how to preserve lysate quality for Western blotting, co-immunoprecipitation, kinase assays, and Parkinson’s disease models without intentionally chelating divalent cations.
-
Acetylcysteine in Redox-Aware Cancer Assays
2026-09-21
Acetylcysteine and N-acetyl-L-cysteine can do more than replenish glutathione: they can reshape how oxidative-stress and nanomedicine assays are interpreted. This guide connects NAC chemistry with practical controls, model selection, and insights from a metastatic breast-cancer nanoplatform study.
-
Dextran sulfate sodium salt: DSS colitis workflow
2026-09-21
Build a reproducible mouse intestinal inflammation model with DSS while separating epithelial injury from mucosal repair. This workflow connects dose control, time-resolved tissue collection, and GPR35–KLF5 pathway assays for ulcerative colitis research and therapeutic screening.
-
ENaC Processing in Rat Kidney: Salt Loading and ADH
2026-09-20
The reference study shows that acute sodium repletion rapidly suppresses processed ENaC in rat kidney despite sustained aldosterone, whereas dDAVP increases both processed and full-length channel subunits. These findings support a model in which sodium loading and ADH regulate ENaC through distinct, aldosterone-independent effects on trafficking and synthesis.
-
Protease Inhibitor Cocktail for ATII Assays
2026-09-19
Protect DRP1, phospho-DRP1, and glycolysis-associated proteins during ATII-cell lysis with an EDTA-free formulation designed for phosphorylation-sensitive workflows. This guide pairs the cocktail with hyperoxia models, Western blotting, co-immunoprecipitation, and metabolic phenotyping while addressing DMSO, phosphatase, and sample-handling variables.
-
mCherry mRNA: Reporter to Translational Readout
2026-09-18
A thought-leadership guide to using Cap 1-capped, modified-nucleotide mCherry mRNA as a mechanistically informed reporter for delivery, formulation, and translational research, with kidney-targeted nanoparticle studies providing a practical framework for validation.
-
NF 449 in Reliable Platelet Assays
2026-09-18
NF 449 (SKU B6716) helps researchers separate ATP-sensitive platelet signaling from nonspecific loss of cellular or platelet viability. This scenario-based guide covers receptor selectivity, assay controls, preparation, interpretation, and practical vendor-selection criteria for reproducible platelet activation and antithrombotic agent research.
-
SN-38 Disrupts FUBP1–FUSE DNA Binding
2026-09-17
The reference study identified camptothecin and SN-38 as inhibitors of the FUBP1–FUSE interaction, adding a transcriptional mechanism to their established topoisomerase I activity. Its biochemical screening and HCC cell experiments suggest that disrupting FUBP1-dependent gene regulation may contribute to the anticancer effects of SN-38, while also defining important limits for translation into other tumor models.
-
Viral RIPK3 Degradation and Proteasome-Linked Inflammation
2026-09-17
The reference study identifies a viral inducer of RIPK3 degradation, or vIRD, that recruits host SCF machinery to ubiquitinate and eliminate the necroptosis kinase RIPK3. By combining viral genetics, biochemical analysis, and genetically defined mouse infections, Liu et al. show that this proteasome-dependent immune-evasion strategy influences necroptosis, inflammation, viral replication, and disease severity.
-
HRP Rabbit Anti-Goat IgG (H+L) Antibody Workflow
2026-09-16
Build sensitive, low-background assays for goat primary antibodies across western blotting, ELISA, dot blot, and tissue staining. This workflow pairs application-specific dilution guidance with controls and troubleshooting for studies such as localized p21 mRNA–LNP research.
-
Protease Inhibitor Cocktail: EDTA-Free Workflow
2026-09-16
Protease Inhibitor Cocktail (EDTA-Free, 200X in DMSO) helps limit protein degradation during extraction and downstream assays while avoiding EDTA, which is useful for phosphorylation and divalent-cation-sensitive workflows. It should not be treated as a universal metalloprotease inhibitor or used without compatibility testing in assays sensitive to DMSO or the inhibitor mixture.
-
Dutasteride: Designing Causal Prostate Assays
2026-09-15
Dutasteride is a dual 5-alpha-reductase inhibitor that can do more than suppress DHT formation: it can anchor a layered, causal assay strategy. This article translates mechanistic and immunometabolic lessons from a recent Arrb2 study into rigorous prostate cancer and BPH research workflows.
-
LNP-Delivered NGFR100W mRNA for Peripheral Neuropathy
2026-09-15
The reference study developed a chemically modified, codon-optimized NGFR100W mRNA and delivered it with lipid nanoparticles to promote nerve repair while reducing the pain associated with wild-type NGF. Its mouse data connect transcript engineering, protein secretion, and functional neuropathy recovery, providing a useful framework for therapeutic mRNA design.
-
Plerixafor (AMD3100): CXCR4 Research Workflows
2026-09-14
Plerixafor (AMD3100) turns CXCL12/CXCR4 biology into a controllable experimental variable for cancer metastasis, stem-cell trafficking, immune-cell redistribution, and platelet–tumor studies. This practical guide connects assay design, formulation, imaging, and troubleshooting to the mechanistic findings of a recent platelet extravasation study.
-
Calnexin Shapes CFTR Variant Rescue
2026-09-14
Tedman et al. used deep mutational scanning to define how the ER chaperone calnexin influences expression and corrector responsiveness across 232 clinical CFTR variants. The study shows that proteostasis is a major, variant-dependent determinant of plasma membrane delivery and pharmacological rescue, providing a framework for interpreting personalized cystic fibrosis treatment responses.